Back to mobile site
Get it on Google Play

MannKind gets FDA approval for inhaled insulin in children ages 6 and up

May 29, 2026 12:30 PM EDT Send to a Friend
MannKind Corporation (NASDAQ: MNKD) announced the U.S. Food and Drug Administration approved Afrezza inhaled insulin for children and adolescents aged ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login